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Abstract 
Gluten-induced aggregation of K562 cells represents an in vitro model reproducing the 
early steps occurring in the small bowel of celiac patients exposed to gliadin. Despite 
the clear involvement of TG2 in the activation of the antigen presenting cells, it is not 
yet clear in which compartment it occurs. Herein we study the calcium-dependent 
aggregation of these cells, using either cell-permeable or cell-impermeable TG2 
inhibitors. Gluten induces efficient aggregation when calcium is absent in the 
extracellular environment, while TG2 inhibitors do not restore the full aggregating 
potential of gluten in the presence of calcium. These findings suggest that TG2 activity 
is not essential in the cellular aggregation mechanism. We demonstrate that gluten 
contacts the cells and provokes their aggregation through a mechanism involving the 
A-gliadin peptide 31-43. This peptide also activates the cell surface associated 
extracellular TG2 in the absence of calcium. Using a bioinformatics approach, we 
identify the possible docking sites of this peptide on the open and closed TG2 
structures. Peptide docks with the closed TG2 structure near to the GTP/GDP site, by 
establishing molecular interactions with the same amino acids involved in stabilization 
of GTP binding. We suggest that it may occur through the displacement of GTP, 
switching the TG2 structure from the closed to the active open conformation. 
Furthermore, docking analysis shows peptide binding with the -sandwich domain of 
the closed TG2 structure, suggesting that this region could be responsible for the 
different aggregating effects of gluten shown in the presence or absence of calcium. 
We deduce from these data a possible mechanism of action by which gluten makes 
contact with the cell surface, which could have possible implications in the celiac 
disease onset.  
  
Introduction 
Celiac disease (CD) is a clinical syndrome of intolerance to dietary wheat gluten that 
occurs in genetically susceptible patients expressing particular HLA-DQ2 or HLA-DQ8 
molecules. Gluten exposure provokes a chronic inflammatory enteropathy, due to 
activation of a specific T-cell lymphocyte immune response in the lamina propria and 
an innate immune reaction in the intestinal epithelia (Green and Cellier 2007), 
characterized by increased numbers of intraepithelial lymphocytes, crypt hyperplasia 
and variable degrees of villous atrophy (Dewar and Ciclitira 2005). Although the role 
of T cells in inducing intestinal damage in CD patients is well established, still poorly 
understood are early stages in which gliadin starts the whole process.  
TG2 plays a central role in the development of celiac disease serving both as a gliadin 
modifying enzyme and as the main target of the autoimmune response of the patient 
(Dieterich et al. 1997). TG2 is a multifunctional mammalian protein with 
transamidase, deamidase and signaling properties depending on cellular localization. 
The transamidation catalytic activity of TG2 is allosterically activated by Ca2+ and 
inhibited by GTP or GDP (Bergamini et al. 2011). Because TG2 inside living cells is 
primarily GTP/GDP-bound, and calcium concentration is low, TG2 is predominantly 
present in a crosslinking-inactive form. Regulation is chiefly brought about by calcium 
and GTP, which stabilize different conformations involved in protein transamidation 
and in cell signaling (Griffin et al. 2001; Zhang et al. 1998). In addition TG2 is secreted 
into the extracellular environment, where it facilitates cell adhesion through a non-
transamidating mechanism via its association with fibronectin, heparan sulfates (HS), 
and integrins (Wang et al. 2012; Wang and Griffin 2012). TG2 is present on the surface 
of tunica propria cells in small bowel tissue sections from both normal and celiac 
subjects (Hodrea et al. 2010). A large pool of extracellular TG2 is inactive under 
normal physiological conditions in cell culture and in vivo (Siegel et al. 2008). In 
antigen-presenting cells, such as dendritic cells and macrophages, large amounts of 
TG2 are bound to the external side of the cell membrane, partly in a catalytically active 
state (Hodrea et al. 2010). However, activation of TG2 in a non-reducing extracellular 
environment may be transient due to oxidation of the enzyme, which leads to 
disulphide bond formation between vicinal Cys370 and Cys371 and TG2 inactivation 
in the open structure (Stamnaes et al. 2010). In the small intestine, extracellular TG2 
inside the lamina propria increased in patients with CD (Skovbjerg et al. 2004a). 
Noteworthy, surface TG2 in the small intestine is typically inactive even though the 
concentrations of calcium and GTP in the extracellular environment should favor TG2 
activity (Siegel et al. 2008). Thus, mechanism of activation of TG2 outside the cells 
remains a deep mystery.  
TG2 activity is involved in the formation of gliadin-TG2 complexes via isopeptide 
bonds between glutamine residues of A-gliadin and specific lysine residues of the 
enzyme (Fleckenstein et al. 2004; Dorum et al. 2010). Cross-linking of gliadin to TG2 
and to other extracellular matrix (ECM) proteins mediated by TG2 activity is well-
documented (Dieterich et al. 2006; Uhlig et al. 1998). In addition to the classic 
complexes stabilized by the usual isopeptide bond, immunogen gliadin peptides can 
also link to TG2 via a thioester bond to the active site cysteine through which they are 
thought to be deamidated and transformed into high affinity binding peptides for 
HLA-DQ2 and HLA-DQ8. Thus they are exposed on the surface of antigen presenting 
cells and presented to gluten-specific CD4(+) T cells (Tjon et al. 2010). Transamidation 
and deamidation of gluten by TG2 can occur simultaneously at physiological pH 
(Fleckenstein et al. 2002). Both sequences 31-43 and 62-75 of the A-gliadin protein 
are linked to TG2 in this manner (Fleckenstein et al. 2004; Dorum et al. 2010). The 
uptake of the peptide 31-43 into cells requires extracellular membrane-bound TG2 
but not the catalytic activity of the enzyme (Caputo et al.  2010). Several possible 
cellular compartments in which the modifications of the gliadin epitopes by TG2 takes 
place have been proposed, such as the brush border, or intracellularly after 
endocytosis of gluten-peptides or gliadin-TG2 complexes (Sollid 2002), and 
extracellularly in the lamina propria (Skovbjerg et al. 2008).  However, it remains to 
be established where and how the TG2 is activated in vivo.  
A concentration-dependent agglutinating effect of bread wheat gliadin occurs in 
human cells of different histotypes (Farré Castany et al, 1995). Treatment of K562 
cells with peptic–tryptic digests of wheat gluten determine their aggregation 
(Auricchio et al. 1984). The agglutination of K562 cells by wheat gliadin peptide is the 
result of a cascade of very early events occurring at the K562-cell surface similar to 
those occurring at the intestinal epithelial surface (Silano et al. 2012). Gluten-induced 
aggregation of the K562 cells occurs through a mechanism that is prevented and 
reversed by amines and polyamines (Auricchio et al. 1990), which are also substrates 
of TG2 (Cordella-Miele et al. 1993). In light of these considerations, TG2 activity plays 
a pivotal role in the mechanism by which gluten induces cellular aggregation. In this 
work, we tried to shed light on the possible mechanism by studying the K562 cells and 
their agglutination in the presence of gluten.   
MATERIALS AND METHODS 
Materials. The pepsin-trypsin digested gluten (PT-glut) was prepared as described 
(van de Wal et al. 1998). Briefly, 1 g of gluten was solubilized in 1M acetic acid and 
boiled for 10 min. Pepsin (P6887, Sigma-Aldrich, St Louis, MO, USA) was added and 
the mixture was incubated for 4 h at 37°C. Subsequently, the pH was adjusted to 7.8 
with NaOH, followed by the addition of trypsin (T8253, Sigma-Aldrich, St Louis, MO, 
USA) and incubation for 4 h at 25°C.  Trypsin activity was stopped by adding the Soy 
Bean trypsin inhibitor. Then the samples were heated at 95°C for 10 min, centrifuged 
at 25°C and the solution dialysed using a cellulose tubular membrane with 12,000-
14,000 cut-off (Membrane Filtration Products Inc, San Antonio, TX, USA) against a 
large excess of water. Bovine serum albumin (A8806, Sigma-Aldrich, St Louis, MO, 
USA) was treated similarly and served as a negative control for peptic-tryptic 
treatment. Protein concentration was determined by using the BCA protein assay 
(Pierce, Thermo Fisher Scientific Inc., Waltham, MA, USA). 
The A-gliadin peptide p31-43 (LGQQQPFPPQQPY) and an unrelated control peptide 
(KRASKRAGTFGGF) were synthesized using the Fmoc chemistry and dissolved in water 
at 20 µg/mL. Purity was determined by high-performance liquid chromatography and 
mass spectrometry. 
Cell-impermeable R281 and cell-permeable R283 active site irreversible inhibitors of 
TG2 (Griffin et al. 2008, Badarau et al.  2015) were dissolved in water at a 
concentration of 0.1 M (stock solution), and aliquots were stored at -80°C until their 
use. The inhibitors were used at a final concentration of 200 μM. 
Cell culture. The human K562 cells were cultured in a humidified atmosphere of 5% 
CO2/air as described (Mischiati et al. 2004).  
Cells agglutination assay.  The K562 cells were harvested by centrifugation, washed 
with Ca2+/Mg2+-free PBS (Sigma-Aldrich, Milan, Italy). In the aggregation test, 2.5 x 106 
cells were suspended in 250 μl of TBS (Tris 100 mM, NaCl 150 mM pH 7.6) in the 
absence or in the presence of PT-glut and incubated at 37°C for 30 min under vigorous 
stirring. When indicated, calcium (10 mM) and/or the TG2 inhibitors were added to 
the cells 15 min before the aggregation test. Cells agglutination take place on the 
stirring bar and aggregated cells were removed easily by a magnet. The remaining 
suspended cells were quantified at 720 nm as described (Mohler et al. 1996) and 
expressed as percent of loaded cells (untreated sample). The percent of aggregated 
cells was calculated by the formula:   
[1 – (OD of residual cells in suspension/OD of untreated loaded cells)]*100 
All experiments were performed at least 3 times in triplicates. 
Total TG2 activity assay. Lysates were prepared from about 2,5 x 106 cells by 
dissolving them in 50 μL of TX100 buffer (5 mM Tris pH 7.6, 0.25M sucrose, 0.2mM 
MgSO4, 2 mM dithiothreitol, 0.4 mM PMSF, 0.4% TX100) at room temperature (RT) 
for 10 min. The activity of TG2 was tested in 25 μg of cell lysate after calcium addition. 
The 96-well plate was prepared by coating the wells with 10 mg/ml dephosphorylated 
dimethyl casein (DMC). Excess of DMC was removed and the wells were washed with 
TBS-T20 (TBS, 0.05% Tween20). Well bottom was saturated in 3% BSA in TBST-T20 for 
1 hr at RT. The transamidation was performed at 37°C for 45 min in a mixture 
containing 100 mM Tris pH 8.5, 10 mM CaCl2, 20 mM dithiothreitol, 1 mM 5-
biotinamidopentylamine (5-BP). After several washes in TBS-T20 containing 1 mM 
EDTA, the wells were filled with 3% BSA in TBS-T20 plus streptavidin-linked alkaline 
phosphatase (1:1000) and left for 1 hr at RT. The AP activity was assayed by using the 
buffer PNPP (100 mM Tris pH 9.5, 0.5 mM zinc acetate, 5 mM MgCl2, and 5mM p-
nitrophenyl phosphate) and the developed color was measured at 405nm within 30 
min. All experiments were performed at least 3 times in duplicates. 
Cell surface TG2 activity measurement. K562 cells grown in the Log-phase were 
collected, washed with Ca2+-free TBS and suspended at 2.5×106 cells/250 l in TBS. 
When appropriated, the cells were pre-incubated with the TG2 inhibitor R281 (200 
M) for 30 min at 37°C before the experiments. To assay the cell surface TG2 activity, 
cells were incubated for 45 min at 37°C in TBS with 1mM 5-BP and 0.2 mg/ml DMC in 
the presence or in the absence of CaCl2 (10 mM). Cell-free supernatants were 
collected by centrifugation at 12000xg for 5 min at 4°C and 15 l of each sample were 
loaded onto 15% SDS polyacrylamide gel for Western blot analysis. Proteins were 
transferred onto nitrocellulose membrane (Hybond C Extra, GE Healthcare Europe 
GmbH, Milan, Italy). The membrane was stained with Ponceau Red to check equal 
load of DMC, followed by blocking with 3% BSA in TBS-T20. Membranes were probed 
with streptavidin-conjugated alkaline phosphatase and developed with 5-Bromo-4-
chloro-3-indolyl phosphate/Nitro blue tetrazolium substrate (SIGMA FAST™ 
BCIP/NBT, Sigma-Aldrich). After 5-10 minutes, the membrane was rinsed in water and 
air-dried for long-term storage.  
Flow cytometry. To assess the mitochondrial membrane potential (Δψm), the cells 
were washed twice and resuspended in PBS containing 0.1 µM 5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1) monomer (Cayman 
Chemicals) at a concentration of 5x105 cells/mL and incubated at 37°C for 15 min. 
Afterwards, the cells were washed twice in PBS and fluorescence was acquired using 
a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA) equipped with a 488 
nm Air-cooled argon-ion laser and then the data were analyzed using the FlowJo 
software (Tree Star Inc., San Carlos, CA). In order to avoid spectral overlap, 
compensations using single color controls were performed. JC-1 fluorescence was 
analyzed on the FL1 (530 nm band-pass filter) and FL2 (585 nm band-pass filter) 
channels for detection of the dye monomer and dimer form, respectively.  The 
analysis of cells with damaged membrane was performed using the LIVE/DEAD 
Viability/Cytotoxicity Kit (Life Technologies, Carlsbad, CA). Cells were resuspended in 
RPMI containing 2 µM calcein AM and 4 µM ethidium homodimer-1  (EthD-1) 
(Cayman Chemicals) at a concentration of 5x105 cells/mL and incubated at 37°C for 
30 min. Afterwards, the cells were analyzed using the flow cytometer. Calcein 
fluorescence was analyzed on the FL1 (530 nm band-pass filter) and EthD-1 
fluorescence was analyzed on the FL3 (670LP long-pass filter). 
Calcium quantification. The presence of calcium in the extracellular fluid was 
investigated by flame atomic absorption spectroscopy performed on an Analyst 800 
(Perkin-Elmer) equipped with a calcium-hallow cathode lamp (Lumina, Perkin-Elmer) 
at the wavelength of 422.7 nm, using a 20 mA cathode current and a slit width of 0.7 
nm. The background correction with a deuterium lamp was applied. The standard 
solutions (500, 1000, 2000, 4000 µM calcium) for the calibration curve were prepared 
by dilution of certified standard solution of calcium with reagent blank (ultrapure 
water, peptide and TBS buffer); a recovery test was performed on the samples by 
adding a known amount of calcium standard and the result was between 95-105%. 
The detection limit of analytical procedure was calculated according to the IUPAC 
Compendium of Analytical Nomenclature Definitive Rules (Inczedy et al. 2002) and it 
was equal to 165 µM. All samples analyzed gave a concentration value lower than the 
detection limit.  
Western blotting. The presence of TG2 in the extracellular media was analyzed by a 
standard western blotting procedure (Mischiati et al. 2015). Cells lysates and 
extracellular media were submitted to SDS-PAGE on a 10% slab gel. The separated 
proteins were blotted to a nitrocellulose membrane, afterwards blocked by 
treatment with 5% defatted dried milk in TBS plus 0.05% tween 20 and stained with 
anti-TG2 monoclonal antibody (CUB7402, Thermo Fisher Scientific, Milan, Italy) and 
peroxidase-conjugated secondary antibody before the development with the luminol 
substrate. All the experiments were performed at least 3 times in duplicates.  
Structural analysis. The bioinformatics analysis of putative A-gliadin peptide 31-43 
interactions at the TG2 protein surface were performed by the PEP-SiteFinder tool 
(PEP-SiteFinder web server:  http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-
SiteFinder). The identification of candidate binding sites was performed on the 
protein surfaces of both closed and open TG2 structures retrieved from the Protein 
Data Bank (PDB), respectively PDB entries 4PYG (Jang et al. 2014) and 2Q3Z (Pinkas et 
al. 2007). Given the peptide sequence, PEP-SiteFinder generated a series of peptide 
conformations (PEP-FOLD program) that were fitted onto the protein structure using 
a blind rigid docking using the ATTRACT2 force field (Fiorucci and Zacharias 2010). At 
the end of the process, the obtained “poses” were ranked by energy. In addition, the 
program returns a propensity index informative about the confidence of the 
prediction and, for each amino acid of the protein, its probability that could interacts 
with the probed peptide. Although the peptide conformations are only approximate, 
the developers have found that this approach is able to identify a correct interaction 
region on the protein surface for close to 90% cases. (Saladin et al. 2014). The 3D 
views of the peptide 31-43 best poses docked to the closed and open TG2 structures 
were performed by using the RasMol software. The protein-peptide interactions were 
analyzed using the Ligand-interaction procedure implemented in the MOE system of 
programs (Molecular Operating Environment – MOE - 2014.09; Chemical Computing 
Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 
2014).  
Statistical analysis. The results were expressed as arithmetic mean  standard 
deviation. Statistical calculations were performed using a one-way ANOVA and the 
differences among groups were examined using the Bonferroni t-test. P value < 0.05 
was considered significant.  
RESULTS 
 
Gluten-induced aggregation of K562 cells is more efficient in the absence of calcium.  
A process of cell recruitment and agglutination is one of the early steps in the celiac 
patient in response to gluten. It has been demonstrated that TG2 is certainly involved 
in the cellular aggregation (Silano et al. 2012), but it is not yet clear whether it is 
involved the intra- or extra-cellular phase, or if its activity is necessary for the 
mechanism by which gluten interacts with the cells. 
In initial experiments we checked the cellular distribution of TG2 in K562 cells, 
discriminating between an intracellular pool of the protein (TG2in) and that associated 
with the outer surface of the cytoplasmic membrane (TG2es), by checking the effects 
of treatment of the cells with R281, an irreversible non-permeable inhibitor of TG2. 
Upon treatment as described, cells were accurately washed in calcium-free 
physiologic solution and lysed in non-denaturing conditions to measure the total 
activity of TG2 (TG2tot) in the lysates following addition of substrates and calcium. 
Data in Fig.1A show that treatment of cells with R281 causes a 60% reduction of the 
TG2tot  activated in vitro by calcium, compared to the untreated cells, testifying that 
the larger fraction of the enzyme is exposed at the cell surface in native cells. As a 
control, addition of the same inhibitor of TG2 to the lysate while performing the assay 
completely abolished TG2 activity, confirming that the fraction of residual activity 
observed in living cells treated with the R281 was due to lack of access of the inhibitor 
to the pool of TG2in.  
Then, we assessed the state of activation of TG2es in K562 cells, in the absence or 
presence of calcium added to the extracellular environment. We suspended the cells 
in physiologic solution containing DMC and 5-BP, in the presence or absence of 
calcium for 45 min, and the supernatant was collected for the analysis of biotin 
incorporation into DMC (Fig.1B). In the absence of calcium, only a small amount of 
TG2 is active compared to that in the presence of calcium. 
Taken together, the data reported in Fig.1A-B show that a large portion of the cellular 
TG2 is exposed on the outer cell surface of K562 cells, chiefly in an inactive state in 
the absence of calcium in the extracellular fluid, but becomes activated  after its 
addition. Since the TG2es can be still activated in the presence of calcium, we can 
exclude that it is in the open-inactive conformation described in the literature 
(Stamnaes et al. 2010). With the current state of knowledge on TG2 structures, by 
exclusion, we indicate that it should be in the closed conformation.   
In an attempt to clarify the role played by TG2 activity in cellular agglutination, we 
carried out a study in the presence or absence of calcium. K562 cells were suspended 
in physiologic solution, in the absence or in the presence of calcium and increasing 
concentrations of gluten added to the cells (up to 60 micrograms/250μL). The result, 
shown in Fig.1C, shows that gluten causes cellular aggregation in a dose-dependent 
manner, with a saturation effect observed only at higher peptide concentration. At 
the concentration of 30μg/250μL PT-glut, cells form a robust aggregate, similar to a 
cotton wool pad, attached to the magnetic bar used during aggregation. The analysis 
of aggregated cells by light microscopy shows the presence of long tangled cords of 
aligned cells (Fig.1C, insert). Surprisingly, at variance with that previously described 
(Silano et al. 2012), in our experiments gluten exerts the maximal aggregative 
potential in the absence rather than in the presence of calcium. Since the presence of 
calcium in the extracellular environment leads to the increase of TG2es activity (see 
Fig.1B), gluten potential for inducing the aggregation of K562 cells seems negatively 
correlated with the TG2es activity. In addition, gluten is a good substrate for TG2 
(Skovbjerg et al. 2002). A possible hypothesis that could explain the effect of calcium 
on cellular aggregation induced by gluten is that TG2, when active (presence of 
calcium), may change the aggregating effect by altering the gluten itself which, in 
turn, can no longer make contact with the cell surface. In an alternative hypothesis, 
gluten could only recognize and bind to the closed-inactive TG2 structure (i.e. absence 
of calcium), as a consequence of the loss of some specific sites of interaction with TG2 
during the switch from the closed-to-open conformation. In the remainder of this 
study, we therefore evaluate which of these hypotheses could be true.  
TG2 activity is not required for cellular agglutination. To dissect further this issue we 
took advantage of the use of TG2 irreversible inhibitors, R281 and R283, which are 
incapable and capable respectively of crossing the cell membrane and block the 
activity of TG2es or TG2tot. By this means, we expected to inhibit the different TG2 
pools selectively so verifying which of them are involved in the cellular agglutination 
mechanism. We suspended the K562 cells in physiologic solution, in the presence or 
absence of TG2 inhibitor and/or calcium, and then the PT-glut was added for 30 min 
whereupon the cellular agglutination was evaluated. The results, reported in Fig.2A, 
do not show any effect of the TG2 inhibitors on the aggregation phenomenon. In a 
control experiment conducted in parallel, we show the effectiveness of the inhibitors 
on the TG2 activity either, by evaluating the TG2es activity in living cells after DMC and 
5-BP addition in the cell suspension media (Fig.2B), or by assaying residual TG2 activity 
in cell lysates after calcium addition (Fig.2C). If the activity of TG2 really facilitates 
cellular agglutination, we expected a recovery of the aggregating potential of gluten 
in the presence of calcium after the treatment with TG2 inhibitors. As shown in the 
Figure 2A, TG2 inhibitors in the presence of calcium did not restore the full 
aggregation potential of gluten observed in the absence of calcium confirming that 
Ca-activated TG2 is not essential for cellular agglutination. 
Effects of A-gliadin peptide 31-43 on cells agglutination and TG2 activity. It is known 
that the A-gliadin peptide 31-43 (p31-43) binds to TG2 (Dorum et al. 2010). Therefore, 
we next investigated whether this region is involved in the cellular agglutination 
induced by gluten in the K562 cells. Aggregation was induced with a single 
concentration of gluten that caused an evident agglutination of these cells 
(30μg/250µl, see Fig.1). The p31-43 was added to the suspension of cells before the 
addition of gluten, at different stoichiometric ratios (0.1 to 50 times) compared to the 
gluten subsequently used to induce cell agglutination. The experiment was conducted 
both in the absence (Fig.3A) and in the presence of calcium (Fig.3B). In a parallel 
experiment, the unrelated peptide and p31-43 when added to the suspension of cells 
in the absence of gluten did not aggregate the cells (data not shown). The results 
showed that the p31-43 reduces by 50% the cellular aggregation, whereas at the same 
concentration an unrelated peptide did not significantly affect the aggregation 
induced by gluten in the absence of calcium. Notably, in the presence of calcium, the 
p31-43 did not change the aggregation induced by gluten, as well as the control 
peptide. This result allows us to highlight the importance of the amino acids 31-43 of 
gliadin in cellular aggregation. Since the 31-43 sequence of gliadin binds to TG2 
(Dorum et al. 2010) and this sequence is important for the interaction of gluten with 
the cell surface (Fig.3A), we consider it reasonable to suggest that gluten might exert 
the aggregating effect through a direct interaction between the 31-43 amino acid 
sequence of gliadin and the TG2es. It is conceivable that the gluten peptide 
preferentially interacts with the closed conformation of TG2. 
In additional experiments we evaluated the activity of TG2es after the administration 
of p31-43. The K562 cells, suspended in physiologic solution in the presence or in the 
absence of calcium, were treated for 30 min in the presence or in the absence of 
increasing concentrations of the p31-43 or of the unrelated peptide. Afterwards, DMC 
and 5-BP were added to the cellular suspension for 45 min at 37°C and the cell-free 
supernatants were isolated for subsequent analysis of the biotinylated DMC (Fig.4A). 
The p31-43 significantly activates the TG2es in the absence of calcium, in a dose-
dependent manner, while the control peptide did not give any significant activation. 
Conversely, in the presence of calcium, the p31-43 did not affect the activation of 
TG2es.  
In addition, we verified whether the conditions required for the assay of TG2es activity 
(i.e. absence of energy source and length of incubation time) provoked energy 
depletion in the K562 cells, which in turn may trigger membrane injury with 
consequent calcium and TG2in leakage into the extracellular solution. To this aim, the 
cells were suspended at 2.5×106/250 l in TBS and incubated for 75 min at 37°C, 
whereupon the cells were pelleted by centrifugation and cell-free supernatants 
separated. The pelleted cells were used to study the energetic state by staining with 
JC-1 before their analysis by flow cytometry. Other cells were incubated for a similar 
time in TBS containing glucose (10 mM) or were assayed immediately after the 
recovery from the cell culture (Fig.4B). Control cells were treated for 15 min in the 
presence of 250 µM carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) 
and the treatment strongly reduced the Δψm in 96.2% of cells as expected. After 75 
min in TBS, only 0.67% of cells result depolarized, a value similar to those obtained in 
cells maintained in TBS containing glucose (0.7%) or directly collected from the cell 
culture (0 min, 0.56%). The absence of a substantial variation of the Δψm indicated 
that the cells did not change their energy state in the time period studied.  
Furthermore, we determined the presence of cells with injured cytoplasmic 
membrane in the cell pellets by staining with EthD-1 and calcein-AM and flow 
cytometry analysis. This analysis discriminates live cells, in which cell-permeant 
calcein-AM is converted to green fluorescent calcein, from cells with damaged 
membrane that are stained red by the cell-impermeable EthD-1. In parallel, other cells 
were incubated for a similar time in TBS containing p31-43 (50X, the max amount used 
above to study the effects on TG2es activity) or were assayed immediately after the 
recovery from the cell culture (Fig.4C). A positive control for membrane damage was 
used where an aliquot of cells was incubated at 50°C for 10 min whereby 99.3% of the 
cells resulted in injury. After 75 min in TBS, cells with compromised membrane were 
4.43%, an amount similar to that obtained for cells incubated for this time in the 
presence of p31-43 (2.85%) or assayed immediately after the recovery from the cell 
culture (3.57%). From this comparison, we deduced that the conditions studied did 
not alter significantly the number of injured cells. 
Afterwards, we determined the presence of calcium or TG2 in the cell-free 
supernatants collected as described above. Calcium presence was assayed in 
supernatants isolated from K562 cells incubated in TBS for 75 min, in the presence or 
in the absence of p31-43 (50X), or at the initial time of treatment (0 min). The flame 
atomic absorption spectroscopy assay gave a detection limit of 165 µM and all the 
samples analyzed gave a value lower than the detection limit (data not shown). In the 
supernatants, we assayed the presence of TG2 by a standard western blotting 
procedure using the CUB7402 anti-TG2 antibody (Fig.4D). An amount of lysed cells, 
proportional to the amount of supernatant checked, was loaded on the same gel and 
considered as the maximal TG2 released after damaging 100% of the cells. The 
presence of TG2 in the extracellular media was excluded.  
All together, these data indicated that the assay of TG2es  activity was not influenced 
by the experimental condition adopted, because there was no appreciable leakage of 
intracellular calcium or TG2in into the extracellular environment. In light of this, we 
concluded that p31-43 effectively induced the TG2es activity in a calcium-free manner.  
Effects of p31-43 on the activity of purified TG2. The effect of p31-43 on the activity 
TG2 was further undertaken on purified guinea pig TG2 by using DMC coated plates 
as described in the Material and Methods section. In a preliminary experiment carried 
out using increasing amounts of TG2 we identified the quantity of TG2 sufficient to 
obtain quantitative assay conditions (Fig.5A). The following experiments were 
performed in the presence of 125 ng of TG2. To determine whether p31-43 activated 
the purified TG2, the enzyme was incubated for 45 min at 37°C in the presence or 
absence of p31-43 (50 µg) in TBS calcium-free or containing calcium (Fig.5B). In the 
absence of calcium the p31-43 was not able to activate the purified TG2, an effect 
that was apparently in contrast with the activation of TG2es observed in living cells in 
calcium-free condition (see Fig.4A). As expected, the presence of calcium activated 
the purified TG2 about 9 fold. Of particular note is the finding that the activity of TG2 
in the presence of calcium strongly increased by the addition of p31-43 (to about 24 
fold). In order to verify whether this activating potential in the presence of calcium 
was peptide-specific, the ability of p31-43 to activate TG2 was compared to that of an 
unrelated peptide (Fig.5C). The results indicate the specific activation of TG2 in the 
presence of p31-43. In summary, these data confirmed the inherent potential of p31-
43 as an activator of TG2. The different behavior of p31-43 on TG2 activation 
suggested that interaction of the enzyme with the cellular membrane could facilitate 
the activation induced by p31-43. 
Identification of A-gliadin peptide 31-43 binding sites on the TG2 protein surface. 
We used a bioinformatics approach to search for putative interaction sites between 
the A-gliadin p31-43 and the surface of the TG2 protein in both the closed and the 
open conformation. As control, a similar search was performed using the unrelated 
peptide. We analysed the 3D structures retrieved from the Protein Data Bank with 
the PEP-SiteFinder. This analysis relies on de novo generation of 3D conformations of 
the input peptide starting from the amino-acid sequence. In order to obtain the 
protein residues having large predicted propensities to be at the peptide-protein 
interface all the conformations obtained for the peptide were submitted to a fast 
blind rigid docking on the complete protein surface of TG2. We have summarized the 
best ten “poses” of p31-43 docked to the closed and open TG2 conformations in the 
3D format shown in Fig.6A. Noteworthy, comparison of the open and closed TG2 
structures evidences a deep difference in the distribution of peptide docking sites. For 
example, the peptide interactions observed in the β-sandwich and β-barrel-2 domains 
in the closed TG2 conformation are absent in the open TG2 structure. Conversely, in 
the open conformation of TG2, strong interaction is suggested with the catalytic core 
domain, in close proximity to the catalytic triad and in the β-barrel-1 domain. 
Comparison of the ten best docking positions of unrelated peptide and p31-43 with 
the closed TG2 (Fig.6A) indicated that these peptide may interact with the protein 
surface at different positions. Interestingly, only the p31-43 seems to contact TG2 in 
a region near to the GDP/GTP site. The possible docking site of p31-43 with the TG2 
in closed conformation is located very near to the GTP binding site (Fig.6B) and could 
share with it some important contact residues (compare also Bergamini et al 2010). 
In Fig.6C the GTP and p31-43 molecules inside their binding pockets are shown, 
together with a schematic view of the ligand-protein interactions. The 
macromolecular backbone is drawn in ribbon-style and only the important residues 
involved in binding are explicitly shown. The gliadin peptide binds to the protein by a 
number of specific interactions which are to be classified as true XH…Y hydrogen 
bonds (X, Y = N, O) with H…Y distances in the range 2.2-2.4 Å, the protein residues 
involved being Arg418, Arg476, Arg478, and Glu539.  A comparison with the GTP-
protein interactions scheme shows that some of these amino acids, i.e. Arg476 and 
Arg 478, also interact with GTP through hydrogen bonding interactions of comparable 
strength. In this last case, these interactions could be better classified as CAHB (= 
charge assisted hydrogen bonds) or salt bridges, because of the involvement of 
charged donor and acceptor groups. The competition of the peptide for the binding 
to Arg476 and Arg 478, that stabilize the GTP inside the TG2 molecule, could 
destabilize and possibly dislodge GTP from its binding site provoking the protein 
rearrangement, which leads to enzyme activation. The interactions with the Arg580 
residue deserves a more detailed discussion. This residue, located at the protein 
surface with its guanidine group pointing towards the external region, is certainly 
important in the GTP binding since it interacts with three GTP hydrogen bonding 
acceptors (X…Y distances: 2.8-3.1 Å). Moreover, a closer inspection of the protein-
gliadin peptide distances reveals that Arg580 is only a short distance away from the 
peptide bond CONH2 group (some 2 Å).  On the basis of these results, this residue not 
only could play an ‘anchoring’ role in the first steps of the binding process for both 
the GTP and A-gliadin peptide 31-43, but it also could be of some importance in the 
competition of the two molecules for the same binding site. The competition between 
GTP and peptide could explain the activation of external cell-surface associated TG2 
shown in Fig.3B.  
 
DISCUSSION 
Celiac Disease is an autoimmune disease caused in genetically susceptible patients by 
the ingestion of peptides derived from the flour of wheat, rye and barley. In the 
chronic enteropathy, intestinal damage is characterized by villous atrophy, crypt cell 
hyperplasia, and lymphocytic infiltration of the lamina propria and epithelium 
(Oberhuber et al. 1999). TG2 is involved in the pathogenesis of celiac disease because 
it alters the structure and properties of gluten peptides as it is well known. Different 
regions of the A-gliadin are TG2 substrates and can be deamidated and/or 
transamidated (Dorum et al. 2010). The transamidation, in particular, is required to 
produce the hybrid gliadin/TG2 peptide that triggers the immune response by 
activation of specific T lymphocytes and starts of symptomatic celiac disease. To form 
the hybrid peptides the presence of active TG2 is necessary and to date, the 
mechanism responsible for the enzyme activation and the cell compartment in which 
it occurs has not yet been elucidated.  
The TG2 protein is present not only within the cell but also on the outside, where it is 
found within the ECM and on the outer cell surface mediating important cellular 
functions such as adhesion, survival and migration through both enzymatic and 
scaffolding activities (Nurminskaya and Belkin 2012). TG2 is present on the surface of 
tunica propria cells in small bowel tissue sections from both normal and celiac 
subjects (Hodrea et al. 2010). Cell agglutination represents an interesting model to 
study the interaction of gluten with the cell surface (Auricchio et al. 1984), as it occurs 
in different type of cells (Farré Castany et al. 1995) through a mechanism that involves 
TG2 (Silano et al. 2012).  
Cell agglutination following treatment with gluten has been well studied in K562 cells. 
These cells have the characteristics of immature monocytes/macrophages, because 
they can differentiate along this lineage if properly stimulated (Lozzio et al. 1981; 
Sutherland et al. 1986). Dendritic cells and macrophages expose large amounts of TG2 
at the external side of the cell membrane, part of which is catalytically active (Hodrea 
et al. 2010). In Fig.1A-B we report an experiment that demonstrates presence of a 
substantial amount of TG2 on the surface of the K562 cells that is partially active. 
However, activation of TG2 in a non-reducing extracellular environment may be 
transient due to oxidation of the enzyme, which leads to disulfide bond formation 
between vicinal Cys370 and Cys371 and TG2 inactivation in the open structure 
(Stamnaes et al. 2010). It therefore remains unclear how this extracellular TG2 is 
activated and why, even if on the surface of macrophages is present much TG2, only 
part of it is active. This partial activation does not fit with the well-known calcium-
dependent mechanism, so deeply investigated on the purified enzyme (Cervellati et 
al. 2012). In the model with the soluble enzyme, the interaction of calcium with its 
binding sites on the closed TG2 structure destabilizes the binding of GTP and gives 
rise to a massive activation of the enzyme with exposure of the active site (Bergamini 
et al. 2011). Conversely, in the case of the membrane-bound enzyme, the regulatory 
properties might be affected by the cell surface heparan sulphates  to which it is 
tethered in its closed  conformation (Wang et al. 2012), since the negatively charged 
heparan sulphates may regulate enzyme activity by competing for calcium (Wang et 
al. 2012). In agreement with these observations, a large part of the cell surface TG2 is 
inactive under normal physiological conditions, even if the concentrations of calcium 
and GTP in the extracellular environment should favor its activity (Siegel et al. 2008). 
Therefore, the mechanism of activation of external cell surface TG2 remains obscure. 
In our experiments we have shown that the interaction of gluten at the surface of 
K562 cells involves the sequence 31-43 of the A-gliadin (Fig.3A), and further, that this 
interaction is particularly prominent in the absence of calcium, namely a condition in 
which the TG2 is inactive and in closed form. As further evidence, through the use of 
inhibitors of TG2, we have shown that the aggregating ability of the gluten is not 
recovered if the TG2 structure is activated by calcium and subsequently inactivated 
by the use of R281 (Fig.2A). By means of these data, we noticed that gluten interaction 
with the cell membrane does not require the presence of active TG2 on its surface. In 
light of the incomplete competition of peptide 31-43 with gluten, we argue that other 
regions of A-gliadin or other peptides present in the proteolysed gluten could be co-
responsible for the aggregation phenomenon. For example, the formation of 
complexes between TG2 and the immune-dominant gliadin peptide 52-65 has been 
described. In the complex, TG2 acts as an acyl acceptor linking the peptides either via 
a thioester bond to the active site cysteine (it is likely to be very unstable if a 
nucleophile is available) or via isopeptide bond formation to particular lysine residues 
of the enzyme (Fleckenstein et al. 2004; Dorum et al. 2010; Skovbjerg et al. 2004b). 
Although our data show that TG2 activity is not essential for the agglutination 
mechanism, the different response of the cells to gluten in the presence or in the 
absence of calcium in the extracellular environment (Fig.1) suggests that the 
structural conformation of TG2 could be an important determinant for cell 
aggregation. In particular, the presence of TG2 in the inactive closed-form on the cell 
surface is required to obtain the maximum efficiency of aggregation. We feel that 
gluten could preferentially recognize and bind to the closed-inactive TG2 structure 
(i.e. absence of calcium), as consequence of the loss of some specific sites of 
interaction with TG2 during the switch to the closed-to-open structure. This 
assumption is not surprising since many of the biological effects exerted by the 
extracellular TG2 do not require its catalytic activity and therefore, presumably, 
occurs in the presence of TG2 in its closed conformation. 
We have also described that treatment with p31-43 surprisingly activates a fraction 
of the cell surface TG2, even in the absence of calcium in the extracellular 
environment (Fig.4A). It is conceivable that larger fragments of gliadin containing the 
sequence 31-43 could act in the same manner. Hence, the sequence 31-43 of gluten 
may recognize TG2 in the closed structure present on cell surface and activates it upon 
interaction. This mechanism is reminiscent of the activating effects of glutamine on 
Factor XIII (Mitkevich et al. 1998). Although the inherent potential of p31-43 as an 
activator of TG2 was further confirmed by the data obtained with the purified enzyme 
(see Fig.5), the different behavior of p31-43 on TG2 activity suggests that the cellular 
membrane could influence its structure and facilitate the activation induced by p31-
43 also in the absence of calcium. Our data indicate that the amount of TG2 activated 
in the presence of the p31-43 is dose-dependent, but lower than that which can be 
activated by calcium (Fig.4A), suggesting not all the cell surface TG2 is activated. In a 
similar fashion, during interaction with the gluten, it is plausible that not all the TG2 
molecules on the cell surface might be activated but only the portion of TG2 in direct 
contact with gluten. This mechanism of selective activation would enable the 
remaining part of TG2 to remain preserved in the closed shape, still capable of 
activation but sheltered from the oxidant extracellular environment in which the 
open form undergoes rapid inactivation through formation of disulfide bridges 
between vicinal cysteines. It has been described that p31-43, entering the intestinal 
epithelial cells by endocytosis, can attain to the lamina propria by apical-to-basal 
passage (Zimmermann et al. 2014) and promotes the migration of dendritic cells in 
this compartment (Chládková et al. 2011). Further, it has also been described that 
epithelial junctional integrity is already compromised in the CD early stages, before 
the disease progresses to chronic enteropathy (Rauhavirta et al. 2014), an event that 
permits to gluten to reach the lamina propria and take contact with professional APC, 
the dendritic cells, to be presented to naïve T-cells after processing.  
In an attempt to understand what is the mechanism by which peptide 31-43 contacts 
the cell surface TG2 leading to its activation, we have performed a bioinformatic 
analysis to identify likely sites of peptide interaction with the TG2 structure in closed 
form (Fig.6A). We paid particular attention to the interaction sites with the peptide 
that vanish in the active form, since their disappearance would be responsible for the 
reduction of cellular aggregation induced by gluten in the presence of calcium 
(Fig.1C). The major differences are noted in the region of -sandwich, which contains 
the amino acids involved in the interaction of TG2 with fibronectin (FN), and the N-
terminal segment of 2-barrel. Notably, cell adhesion to the ECM necessitates the 
region of the -sandwich (Akimov and Belkin 2001) and does not require the presence 
of active TG2 (Wang et al. 2010). This is very reminiscent of what happens during cell 
agglutination, in which the cells adhere to gluten (Fig.1C) through a mechanism that 
occurs optimally in the absence of calcium. The interaction of peptide 31-43 with the 
cell surface bound TG2 could compete for the arginine bonds responsible for the 
stabilization of GTP in its pocket (Fig.4C), which in turn determines the passage of TG2 
from the closed to the open structure in the presence of gluten. This in turn could 
reduce the pool of closed inactive TG2 at the cell surface that in its inactive closed 
conformation binds to cell surface heparan sulphates and integrins facilitating cell 
adhesion and survival (Telci et al. 2008; Wang et al. 2010; Wang et al. 2012). The 
gliadin peptide could abolish these cell survival mechanisms, provoking the intestinal 
damage observed in the celiac patients in the early stages of the disease. Likewise, 
interaction of peptide 31-43 with the GTP binding site (Fig.4B) could compete for the 
arginine bonds responsible for the stabilization of GTP in its pocket (Fig.4C), which in 
turn determines the passage of TG2 from the closed to the open structure in the 
presence of gluten. This transition would lead to the activation of TG2 on the surface 
of macrophages in the absence of calcium and thus allow for the formation of cross-
links between TG2 and gluten necessary to trigger the immune response. 
In conclusion, the data reported in this work has shown that gluten interacts with the 
cell surface through the amino acids sequence 31-43 of A-gliadin and makes contact 
with the cell surface TG2 in the inactive form. This interaction is able to activate the 
cell surface TG2. The activation of cell surface TG2 by gluten could be involved in the 
triggering of celiac disease. 
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FIGURE CAPTIONS 
Figure 1. Gluten-induced aggregation of K562 cells.  (A) Analysis of total cellular TG2 
activity. Cells were suspended in calcium-free solution in the presence or in the 
absence of TG2 inhibitor R281, and then lysed. Total cellular TG2 activity in the lysates 
was assayed after addition of calcium. As control, the cell-impermeable TG2 inhibitor 
was added while performing the assay to abolish any TG2 activity (asterisked 
experimental points).  (B) Basal and calcium-induced cell surface TG2 activity. Cells 
were suspended in the presence or absence of calcium for 45 min in physiologic 
solution containing DMC and 5-BP. Supernatant was collected for the analysis of 
biotin incorporation into DMC. Casein transferred on the membrane was stained by 
Red Ponceau and biotinylated DMC was evidenced after the addition of streptavidin-
alkaline phosphatase and BCIP/NBT. (C)  Calcium-dependent cellular agglutination. 
Cells suspended in physiologic solution, in the absence or in the presence of calcium, 
were added with increasing concentrations of gluten. Aggregated cells were 
expressed as percent of the total cells. Right inset: macroscopic visualization of 
gluten-induced cellular aggregate. Magnification: aspect of agglutinated cells by light 
microscope (40x). 
Figure 2. Role of TG2 activity in gluten-induced aggregation of K562 cells. (A) Effects 
of TG2-inhibitors on cellular agglutination. Cells were suspended in calcium-
supplemented or calcium-free solution, in the presence or absence of R281 or R283, 
and then cellular agglutination was induced by gluten addition (30 µg/250µl). 
Aggregated cells were evaluated after 30 min. (B) Effective inhibition of cell surface 
calcium-induced TG2 activity in living cells. The activity was measured after DMC and 
5-BP addition in the cell suspension media and staining of biotinylated blotted casein. 
(C) TG2 activity in cell lysates after the treatment of cells with TG2 inhibitors R281 and 
283. Calcium was added to the cells lysates to activate the residual TG2 before the 
enzymatic assay. 
Figure 3. Dose-dependent effects of peptide 31-43 on the gluten-induced aggregation 
of K562 cells. The peptide was added to the cell suspension at different stoichiometric 
ratio (0.1 to 50 times compared to the gluten) before the addition of gluten 
(30μg/250µl), (A) in the absence or (B) in the presence of calcium. Aggregation was 
expressed as percent of agglutinated cells with respect to total cells. Aggregation in 
the presence of p31-43 or control peptides was up to 2%.  
 
Figure 4. Effects of p31-43 on the activity of cell surface TG2. (A) Dose-effect analysis. 
The peptide was added to the cell suspension for 75 min at 37°C at the indicated 
amount (1-50X) in the presence of casein and 5-BP. Afterwards, cells were collected 
and the supernatants were isolated for subsequent analysis of the biotinylated casein. 
(B) Analysis of the mitochondrial membrane potential by flow cytometry after 
staining with JC-1. The investigation was carried out on cells at time 0 and after 
incubation at 37°C for 75 min in the presence or in the absence of glucose in the 
resuspension solution. (C) Detection of cells with damaged membrane by flow 
cytometry after staining with ethidium dimer and calcein. The investigation was 
carried out on cells at time 0 and after incubation at 37°C for 75 min in the presence 
or in the absence of p31-43 (50X). (D) Western blotting assay of TG2 released from 
the K562 cells after 75 min at 37°C. The presence of TG2 in the extracellular solution 
was assayed at time 0 (0) and after 75 min in the presence (P-75) or in the absence 
(0-75) of p31-43 (50X). As a positive control, the presence of TG2 was evidenced in 
lysed cells pelleted at the time 0.  
Figure 5. Effects of p31-43 on the activity of purified guinea pig TG2. A. Dose-
dependent increase of absorbance within the tested range of different amounts of 
TG2. The assay reported in B and C panels were performed by using 125 ng of TG2. B. 
Differential effect of p31-43 on TG2 activation in the presence or in the absence of 
Ca2+.  The fold increase in activity was calculated with respect to the activity 
measured in the absence of Ca2+. C. Peptide-specific activation of TG2 in the presence 
of Ca2+ and increasing amounts of the p31-43 peptide.  
Figure 6. Bioinformatic analysis of putative points of interaction between the A-
gliadin peptide 31-43 and the TG2 structure. (A) Docking of the peptide structures 
generated in silico (p31-43, orange spheres; unrelated peptide, green spheres) with 
the TG2 structures retrieved from the protein data bank (pdb). The square box 
highlights the GTP bound to the closed TG2 structure. In the closed TG2 structure 
docked with p31-43: the dotted square box was magnified in panel B. (B) 
Magnification of GTP-binding task, in which the GTP-associated closed-TG2 structure 
was superimposed with a calculated peptide 31-43 pose (shown as sticks) found very 
close to the GTP (shown as colored spheres) binding site. (C) GTP and peptide 31-43 
molecules inside their binding pockets are shown, together with a schematic view of 
the ligand protein interactions. The macromolecular backbone is drawn in ribbon-
style and only the important amino acids residues involved in the binding are explicitly 
shown. Interaction schemes’ legenda: green circles, apolar residues; pink circles, polar 
residues (red contour: acidic, blue contour: basic); green arrows, sidechain 
donor/acceptor; blue arrows, backbone donor/acceptor. 
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